Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03368690
Other study ID # N201706026
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 28, 2017
Est. completion date August 23, 2019

Study information

Verified date June 2019
Source Taipei Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study, the investigators will investigate the effects of polyphenolic extract from pine bark on the inattention and hyperactivity in patients with attention deficit hyperactivity disorder (ADHD) based on antioxidative status.


Description:

Attention deficit hyperactivity disorder (ADHD) is a disorder characterized by developmentally inappropriate levels of impulsive behavior, hyperactivity and/or inattention. It is one of the most prevalent chronic pediatric neurodevelopmental conditions. The pathology of ADHD may relate to the oxidative stress caused by abnormal neurotransmitters. Therefore, we would like to intervene pine bark extract (PE) which can improve the symptom of inattention and hyperactivity from the psychological assessment and antioxidative status.

20 children and adolescent aged above 7 but under 20 years old and 20 adults aged from 20 to 65 years old with ADHD will be enrolled in this randomized, double-blind, cross-over and placebo controlled 10-weeks period experiment.

At the treatment period (0th to 4th week of the experiment), children and adolescent with ADHD will receive 1~2 placebo or capsules of polyphenolic extract from pine bark (25mg Oligopin per capsule) according to their body weight. On the other hand, adult with ADHD will receive 2~3 placebo or capsules of polyphenolic extract from pine bark (50mg Oligopin per capsule). The 5th to 6th week will be the washout period. The control group and Oligopin group will be cross-over at 7th week to 10th week of the experiment. Psychiatric examination and nutrition status evaluation will be carried out in this study. At the beginning, 4th, 7th and 10th week of the study, basic psychiatric examination will be carried out by clinical psychologist. Routine laboratory parameter including liver function, kidney function, lipid profile, antioxidative status and iron status will be investigated at the beginning, 4th and 10th week of the study. The nutrition status evaluation including food frequency questionnaire and three-day dietary record (two days on weekdays, one day on holiday). The food frequency questionnaire will be performed at the beginning, 4th, 7th and 10th of the experiment while three-day dietary record will be performed at 2th, 4th , 8th and 10th of the experiment. We expect that polyphenolic extract from pine bark may improve oxidative status which in turn ameliorate the attention and emotional stability in patients with ADHD.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date August 23, 2019
Est. primary completion date June 21, 2019
Accepts healthy volunteers No
Gender All
Age group 7 Years to 64 Years
Eligibility Inclusion Criteria:

1. Children or adolescent with attention deficit hyperactivity disorder (ADHD) whose age reach 7 but under 20 and were not treated with ADHD drugs, antihypertensive drugs and dietary supplements more than 4 weeks.

2. Adults with attention deficit hyperactivity disorder (ADHD) aged from 20 to 65 and were not treated with antihypertensive drugs and dietary supplements more than 4 weeks.

Exclusion Criteria:

1. Children or adolescent treated with ADHD drugs, antihypertensive drugs and dietary supplements

2. Adults treated with antihypertensive drugs and dietary supplements

3. Nervous system diseases (including brain or other central nervous system diseases, e.g. epilepsy)

4. Autism spectrum disorder

5. Intellectual disability

6. Other mental disorders (e.g. Schizophrenia, Bipolar Disorder, Major depressive disorder, Anxiety Disorder, Personality disorders, Conduct disorder, Tourette Syndrome.)

7. Hepatic, renal, gastrointestinal and cardiovascular disorders

8. Biochemical abnormality

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Oligopin®
At the treatment period (0th to 4th week of the experiment), subjects with ADHD will receive 1~3 capsules of polyphenolic extract from pine bark (25mg or 50 mg Oligopin per capsule) according to their body weight and age. The 5th to 6th week will be the washout period. The control group and Oligopin group will be cross-over at 7th week to 10th week of the experiment.
Other:
Placebo
At the treatment period (0th to 4th week of the experiment), subjects with ADHD will receive 1~3 capsules of polyphenolic extract from pine bark (25mg or 50 mg Oligopin per capsule) according to their body weight and age. The 5th to 6th week will be the washout period. The control group and Oligopin group will be cross-over at 7th week to 10th week of the experiment.

Locations

Country Name City State
Taiwan Taipei Medical University - Shuang Ho Hospital New Taipei City
Taiwan Taiwan Adventist Hospital Taipei City

Sponsors (1)

Lead Sponsor Collaborator
Taipei Medical University

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Swanson, Nolan and Pelham Teacher and Parent Rating Scale (SNAP-IV) It is used to evaluate the inattention, impulsivity and hyperactivity for children and adolescent with ADHD as rated by parents and teachers. When Inattention/Hyperactivity-impulsivity subscales approach P85, the participants are going to the next steps.
When subjects took Oligopin that scores decrease significantly than beseline on inattention.
at the start of the experiment and at the 4th, 7th and 10th week
Primary Adult ADHD Self-Report Scale-V1.1 (ASRS-V1.1) or Individual Subjective Perception Job Stress Scale (ISPJSS) It is used to evaluate the inattention, impulsivity and hyperactivity for adult with ADHD as rated by participants. The scores of ASRS-V1.1 more than 17, that can be going to the next steps.
When subjects took Oligopin that scores decrease significantly than beseline on impulsivity and hyperactivity.
at the start of the experiment and at the 4th, 7th and 10th week
Primary Conners' Continuous Performance Test (CPT-III) It is used to evaluate the inattention, impulsivity and vigilance for subjects with ADHD. T-score > 60 approach clinical standard.
In the part of inattention, during supplementation of PE all sub-items were no difference when compared with baseline and sub-items of commissions were lower than placebo group (p<0.05). Hyperactivity results were the same with part of inattention.
at the start of the experiment and at the 4th, 7th and 10th week
Primary Wechsler Memory Scale , WMS-III Use Wechsler memory test to evaluate performance progressing in concentration and impulse control for adults
Among the result of WMS, there were no significant difference in each period.
at the start of the experiment and at the 4th, 7th and 10th week
Primary Wisconsin Card Sorting Test, WCST Use Wisconsin card test to evaluate performance progressing in concentration, impulse control for adults
Among the results of WCST, there were no significantly difference between each group.
at the start of the experiment and at the 4th, 7th and 10th week
Secondary Liver function Serum AST,ALT and bilirubin-total are in units per liter.
there were no difference in each group.
at the start of the experiment and at the 4th, 10th week
Secondary Kidney function Serum BUN,Creatine and urine acid are in milligram per deciliter
there were no difference in each group.
at the start of the experiment and at the 4th, 10th week
Secondary Lipid profile Serum HDL-Cho, LDL-Cho, triglyceride and total cholesterol are in milligram per deciliter
there were no difference in each group.
at the start of the experiment and at the 4th, 10th week
Secondary Hematology Serum WBC in 1000/uL , RBC in 1000000/uL, hemoglobin in gram per deciliter, hematocrit in percentage , MCV in femtoliter , MCH in picogram, MCHC in gram per deciliter, platelet in 1000/uL ; neutrophils, lymphocytes, monocytes, eosinophils and basophils are in percentage.
there were no difference in each group.
at the start of the experiment and at the 4th, 10th week
Secondary Iron status Serum iron, ferritin and TIBC are in microgram per deciliter
there were no difference in each group.
at the start of the experiment and at the 4th, 10th week
Secondary Antioxidative status Thiobarbituric acid-reactive substance, glutathione/oxidized glutathione ratio ,and plasma 8-isoprostane.
During PE supplementation, plasma TBARS level was significantly lower than placebo group (p < 0.05), and there was no significant difference between baseline and PE group.
During PE supplementation, GSH / GSSG ratio in red blood cells was significantly higher than baseline and placebo group (p < 0.05), but there was no significantly difference between baseline and placebo group.
After 4 weeks of supplementation PE and Placebo, the results of plasma 8-isoprostane level were shown in Figure 7C. There was no significantly difference in each group.
at the start of the experiment and at the 4th, 10th week
Secondary Food frequency questionnaire To analyze nutrition status of participants.
the frequency of staple foods, vegetables, fruits and milk intake insufficient in one day.
at the beginning, 4th, 7th and 10th of the experiment
Secondary Three-day dietary record. To analyze nutrition status of participants.
The intake of carbohydrates and fat of three major nutrients was insufficient and protein was excessive.
In terms of vitamins, vitamin B1, vitamin B2, vitamin E consumed appropriately, vitamin B6, vitamin A consumed excessively, Vitamin C was insufficient.
In micronutrients, calcium and iron was insufficient, and sodium, zinc and magnesium consumed in moderation.
at 2nd , 4th, 6th and 10th week of study
See also
  Status Clinical Trial Phase
Completed NCT03148782 - Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase N/A
Recruiting NCT06038942 - Formal Versus Informal Mindfulness Among University Students With Self-reported ADHD, Nonsuicidal Self-injury, or Stress N/A
Not yet recruiting NCT06456372 - Digital Health Intervention for Children With ADHD N/A
Completed NCT05518435 - Managing Young People With ADHD in Primary Care Study
Active, not recruiting NCT04978792 - Does Cultivating Self-compassion Improve Resilience to Criticism and Improve Mental Health in Adults With ADHD? N/A
Completed NCT03216512 - Effects of Noise Cancelling Headphones on Neurocognitive and Academic Outcomes in ADHD N/A
Completed NCT02900144 - Modified Comprehensive Behavioral Intervention for Tics (M_CBIT) N/A
Not yet recruiting NCT02906501 - Effect of Risperidone on Cognitive Functions in Adolescents With ADHD and Behavioral Disturbances N/A
Completed NCT02829528 - Little Flower Yoga for Kids: Evaluation of a Yoga and Mindfulness Program for Children With Increased Levels of Emotion Dysregulation and Inattention N/A
Completed NCT02562469 - ACTIVATE: A Computerized Training Program for Children With ADHD N/A
Terminated NCT02271880 - Improving Medication Adherence in ADHD Adolescents N/A
Recruiting NCT02255565 - Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study Phase 4
Completed NCT02463396 - Mindfulness Training in Adults With ADHD N/A
Completed NCT01673594 - Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist Phase 4
Terminated NCT01733680 - Amiloride Hydrochloride as an Effective Treatment for ADHD Early Phase 1
Completed NCT02300597 - Internet-based Support for Young People With ADHD and Autism - a Controlled Study N/A
Active, not recruiting NCT01137318 - Combined Cognitive Remediation and Behavioral Intervention for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD) Phase 2
Completed NCT01404273 - Functional MRI of Relaxation Response Training in Adults With Attention-Deficit/Hyperactivity Disorder N/A
Completed NCT00573859 - The Reinforcing Mechanisms of Smoking in Adult ADHD Phase 1/Phase 2
Completed NCT00586157 - Study of Medication Patch to Treat Children Ages 6-12 With ADHD Phase 4